Sign inJoin waitlistJoin the waitlist

Ronald Paquette

Clinical Director · Cedars-Sinai Medical Center

Credentials: · · · ·

History

Cedars-Sinai Medical Center
Present

Santa Monica-UCLA Medical Center
1987–1989
Internal Medicine
1984–1987
Ohio State University College of Medicine
1980–1984
University of Notre Dame
1976–1980

Research

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
New England Journal of Medicine · 2012 · 1,753 citations
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
New England Journal of Medicine · 2006 · 1,365 citations
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
Blood · 2002 · 913 citations

Hagop Kantarjian
15 papers
Jaroslaw Maciejewski
14 papers
CS
Charles Sawyers
12 papers
MT
Moshe Talpaz
11 papers
Harold Koeffler
10 papers
Michael Deininger
10 papers
AL
Alan List
9 papers
Jorge Cortes
9 papers
Mikkael Sekeres
9 papers
Neil Shah
9 papers · 1 as a fellow
Robert Vescio
9 papers
SV
Srdan Verstovsek
9 papers

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $498.7K · University of California Los Angeles
1997–2001
Myeloid Specific Regulation of Igg Fc Receptor Type i
National Heart, Lung, and Blood Institute · K08
Contact PI · $406.4K · University of California Los Angeles
1993–1999

Clinical trials

Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
Principal investigator · Recruiting · Phase 1
Ronald Paquette
2023–2028
Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
Principal investigator · Active not recruiting · Phase 2
Ronald Paquette
2022–2027
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
Principal investigator · Unknown · Phase 2
Jonsson Comprehensive Cancer Center
2005
Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
Principal investigator · Completed · Phase 3
Jonsson Comprehensive Cancer Center
2004–2005